Article
The “Skinny Label” Lesson: Hikma Applied To Functional Food And Beverage Brands
The U.S. Supreme Court's unanimous June 4, 2026, decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, clarified the standard for induced patent infringement under 35 U.S.C. § 271(b).
Barnes & Thornburg LLP